363 related articles for article (PubMed ID: 30570827)
1. Impact of Cyclic Citrullinated Peptide Antibody Level on Progression to Rheumatoid Arthritis in Clinically Tested Cyclic Citrullinated Peptide Antibody-Positive Patients Without Rheumatoid Arthritis.
Ford JA; Liu X; Marshall AA; Zaccardelli A; Prado MG; Wiyarand C; Lu B; Karlson EW; Schur PH; Deane KD; Sparks JA
Arthritis Care Res (Hoboken); 2019 Dec; 71(12):1583-1592. PubMed ID: 30570827
[TBL] [Abstract][Full Text] [Related]
2. Clinical diagnostic significance of 14-3-3η protein, high-mobility group box-1, anti-cyclic citrullinated peptide antibodies, anti-mutated citrullinated vimentin antibodies and rheumatoid factor in rheumatoid arthritis.
Huang J; Zeng T; Zhang X; Tian Y; Wu Y; Yu J; Pei Z; Liu Y; Hu T; Tan L
Br J Biomed Sci; 2020 Jan; 77(1):19-23. PubMed ID: 31433746
[No Abstract] [Full Text] [Related]
3. Anti-cyclic citrullinated peptide antibody is highly associated with rheumatoid factor and radiological defects in rheumatoid arthritis patients.
Sulaiman FN; Wong KK; Ahmad WAW; Ghazali WSW
Medicine (Baltimore); 2019 Mar; 98(12):e14945. PubMed ID: 30896663
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis.
Chang PY; Yang CT; Cheng CH; Yu KH
Int J Rheum Dis; 2016 Sep; 19(9):880-6. PubMed ID: 25940989
[TBL] [Abstract][Full Text] [Related]
5. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
[TBL] [Abstract][Full Text] [Related]
6. Relatives without rheumatoid arthritis show reactivity to anti-citrullinated protein/peptide antibodies that are associated with arthritis-related traits: studies of the etiology of rheumatoid arthritis.
Young KA; Deane KD; Derber LA; Hughes-Austin JM; Wagner CA; Sokolove J; Weisman MH; Buckner JH; Mikuls TR; O'Dell JR; Keating RM; Gregersen PK; Robinson WH; Holers VM; Norris JM
Arthritis Rheum; 2013 Aug; 65(8):1995-2004. PubMed ID: 23754702
[TBL] [Abstract][Full Text] [Related]
7. Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis.
Baecklund E; Backlin C; Rönnelid J; Toes R; Huizinga T; Åhlin E; Askling J; Hochberg FH; Klareskog L; Kay J; Smedby KE
Scand J Rheumatol; 2018 Jul; 47(4):270-275. PubMed ID: 29336646
[TBL] [Abstract][Full Text] [Related]
8. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
[TBL] [Abstract][Full Text] [Related]
9. Anti-cyclic citrullinated peptide antibodies are associated with radiographic damage but not disease activity in early rheumatoid arthritis diagnosed in 2006-2011.
Ziegelasch M; Boman A; Martinsson K; Thyberg I; Jacobs C; Nyhäll-Wåhlin BM; Svärd A; Berglin E; Rantapää-Dahlqvist S; Skogh T; Kastbom A
Scand J Rheumatol; 2020 Nov; 49(6):434-442. PubMed ID: 32856532
[No Abstract] [Full Text] [Related]
10. Economic Evaluation of Anticyclic Citrullinated Peptide Positivity in Rheumatoid Arthritis.
An J; Bider-Canfield Z; Kang J; Alemao E; Connolly SE; Lin AT; Cheetham TC
J Manag Care Spec Pharm; 2019 Apr; 25(4):469-477. PubMed ID: 30917075
[TBL] [Abstract][Full Text] [Related]
11. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
12. Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry.
Huang S; He X; Doyle TJ; Zaccardelli A; Marshall AA; Friedlander HM; Blaustein RB; Smith EA; Cui J; Iannaccone CK; Mahmoud TG; Weinblatt ME; Dellaripa PF; Shadick NA; Sparks JA
Clin Rheumatol; 2019 Dec; 38(12):3401-3412. PubMed ID: 31410660
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the diagnostic potential of three anti-citrullinated protein antibodies as adjuncts to rheumatoid factor and CCP in a cohort of South African rheumatoid arthritis patients.
Meyer PWA; Ally MTM; Hodkinson B; Anderson R; Tikly M
Rheumatol Int; 2018 Jun; 38(6):993-1001. PubMed ID: 29713794
[TBL] [Abstract][Full Text] [Related]
14. Rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibodies with hepatitis B and hepatitis C infection: Review.
Zengin O; Yıldız H; Demir ZH; Dağ MS; Aydınlı M; Onat AM; Kısacık B
Adv Clin Exp Med; 2017 Sep; 26(6):987-990. PubMed ID: 29068601
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis.
Zeng X; Ai M; Tian X; Gan X; Shi Y; Song Q; Tang F
J Rheumatol; 2003 Jul; 30(7):1451-5. PubMed ID: 12858440
[TBL] [Abstract][Full Text] [Related]
16. Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays.
Vos I; Van Mol C; Trouw LA; Mahler M; Bakker JA; Van Offel J; De Clerck L; Huizinga TW
Clin Rheumatol; 2017 Jul; 36(7):1487-1492. PubMed ID: 28578492
[TBL] [Abstract][Full Text] [Related]
17. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis.
van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Toes RE; Huizinga TW
Arthritis Res Ther; 2005; 7(5):R949-58. PubMed ID: 16207336
[TBL] [Abstract][Full Text] [Related]
18. Combination of anti-citrullinated protein antibodies and rheumatoid factor is associated with increased systemic inflammatory mediators and more rapid progression from preclinical to clinical rheumatoid arthritis.
Lingampalli N; Sokolove J; Lahey LJ; Edison JD; Gilliland WR; Holers VM; Deane KD; Robinson WH
Clin Immunol; 2018 Oct; 195():119-126. PubMed ID: 29842946
[TBL] [Abstract][Full Text] [Related]
19. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.
van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Huizinga TW; Toes RE; de Vries RR
Arthritis Rheum; 2006 Apr; 54(4):1117-21. PubMed ID: 16572446
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting.
Bemis EA; Demoruelle MK; Seifert JA; Polinski KJ; Weisman MH; Buckner JH; Gregersen PK; Mikuls TR; ODell JR; Keating RM; Deane KD; Holers VM; Norris JM
Ann Rheum Dis; 2021 Feb; 80(2):154-161. PubMed ID: 32928740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
